Phase 2 Study Shows Promising Results for Potential Mucus Clearance Drug

A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells. – Published on June 7, 2018 | Cystic Fibrosis Foundation® News A new […]

Continue Reading

Spyryx SPX-101 Phase 2 HOPE-1 Trial Shows Improvement in Lung Function in Patients with Cystic Fibrosis via Novel Modulation of ENaC

Inhaled drug can be used regardless of a patient’s particular CF mutation. – DURHAM, N.C., June 6, 2018 /PRNewswire/ — Today Spyryx shared positive data for the first cohort of the SPX-101 Phase 2 clinical trial HOPE-1 (Hydration for Optimal Pulmonary Effectiveness), which showed that treatment with SPX-101 in patients with cystic fibrosis (CF) resulted […]

Continue Reading

Data from Spyryx Biosciences’ HOPE-1 Phase 2 Clinical Trial to be Presented in a Late-Breaking Oral Presentation at the 41st European Cystic Fibrosis Conference

DURHAM, N.C. – May 8, 2018 — Spyryx Biosciences, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for severe pulmonary diseases, will present data from the first cohort of its ongoing Phase 2 clinical trial, HOPE-1, in a late-breaking oral presentation at the 41st European Cystic Fibrosis Conference. The data will be presented by Isabelle […]

Continue Reading